ImmunoGuide® Enzyme immunoassay (ELISA) for the determination of free Certolizumab pegol (Cimzia®) in serum and plasma.<br><br>
The drug Certolizumab pegol (trade name Cimzia®) is a tumor necrosis factor alpha (TNF-α) blocker and binds to human TNF-α with a KD of 90pM. Certolizumab pegol is a recombinant, humanized antibody Fab' fragment, with specificity for TNF-α, conjugated to an approximately 40kDa polyethylene glycol (PEG2MAL40K). The Fab' fragment is manufactured in E. coli and is subsequently subjected to purification and conjugation to PEG2MAL40K, to generate Certolizumab pegol.<br><br>
The ImmunoGuide Certolizumab pegol ELISA (mAb-based) kit can be efficiently used for measuring free Certolizumab pegol levels in serum and plasma. For research use only, not for use in diagnostic procedures.
- Assay Description:
- 1 hour incubation (RT) + 1 hour (RT) + 30 min. (RT) + 10 min. (RT) = 2 hours, 40 min. total incubation time
- Catalog number:
- TM09023
- configuration:
- 96 Determinations, 12x8 removable strips
- controls:
- None provided
- design:
- Enzyme immunoassay (ELISA) technique
- FDA Status:
- For research use only, not for use in diagnostic procedures
- MSDS:
- Available upon request
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Other names:
- Cimzia®
- Protocol:
- Sample types:
- Serum and plasma
- Sample volume:
- 10 µL
- standards:
- 5 standards, concentrated - require dilution prior to use
- Standard range:
- 0 / 6 -200 ng/mL
- storage:
- 2 - 8 °C
- sensitivity:
- 2 ng/mL
- Species:
- Human
- Products related:
- Additional info:
